Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 12, 2022

SELL
$57.92 - $72.58 $430,982 - $540,067
-7,441 Closed
0 $0
Q2 2021

Aug 06, 2021

SELL
$63.47 - $69.35 $45,317 - $49,515
-714 Reduced 8.76%
7,441 $512,000
Q1 2021

May 13, 2021

SELL
$60.0 - $68.46 $13,500 - $15,403
-225 Reduced 2.68%
8,155 $527,000
Q4 2020

Feb 12, 2021

SELL
$56.65 - $64.55 $54,327 - $61,903
-959 Reduced 10.27%
8,380 $488,000
Q2 2020

Aug 14, 2020

SELL
$72.34 - $84.0 $7,234 - $8,400
-100 Reduced 1.06%
9,339 $719,000
Q1 2020

May 13, 2020

BUY
$62.63 - $80.22 $9,081 - $11,631
145 Added 1.56%
9,439 $706,000
Q4 2019

Feb 14, 2020

SELL
$61.62 - $67.78 $149,674 - $164,637
-2,429 Reduced 20.72%
9,294 $604,000
Q2 2019

Aug 15, 2019

SELL
$61.87 - $69.38 $18,561 - $20,814
-300 Reduced 2.5%
11,723 $792,000
Q1 2019

May 08, 2019

SELL
$62.53 - $70.05 $4.7 Million - $5.27 Million
-75,199 Reduced 86.22%
12,023 $782,000
Q4 2018

Feb 15, 2019

BUY
$60.54 - $79.0 $57,331 - $74,813
947 Added 1.1%
87,222 $5.46 Million
Q3 2018

Nov 09, 2018

BUY
$71.28 - $78.92 $80,546 - $89,179
1,130 Added 1.33%
86,275 $6.66 Million
Q2 2018

Aug 14, 2018

BUY
$64.88 - $75.68 $295,009 - $344,116
4,547 Added 5.64%
85,145 $6.03 Million
Q1 2018

May 14, 2018

BUY
$72.84 - $88.8 $495,821 - $604,461
6,807 Added 9.22%
80,598 $6.08 Million
Q4 2017

Feb 13, 2018

BUY
$71.15 - $83.52 $108,859 - $127,785
1,530 Added 2.12%
73,791 $5.29 Million
Q3 2017

Nov 13, 2017

BUY
$72.11 - $85.47 $5.21 Million - $6.18 Million
72,261
72,261 $5.86 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $83.5B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Peak Asset Management, LLC Portfolio

Follow Peak Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Peak Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Peak Asset Management, LLC with notifications on news.